Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Parkin and α-synuclein Linked Through Synphilin-1
1 October 2001. One of the hallmarks of sporadic Parkinson's disease (PD) are Lewy bodies (LB), neuronal cytoplasmic inclusions that contain ubiquitinated proteins. Recently researchers have focused on two key LB components, the 16 kDa α-synuclein, and the ubiquitin-ligase parkin, because mutations in both of these proteins are responsible for familial forms of PD. Though a 22 kDa posttranslationally modified form of α-synuclein is ubiquitinated by parkin ( Shimura et al.), attempts to connect the ligase to unmodified α-synuclein have so far proven unsuccessful.

Work from the lab of Ted and Valina Dawson at Johns Hopkins University, Baltimore, Maryland, published today in Nature Medicine, now reveals that parkin interacts with the α-synuclein-associated protein synphilin-1, another LB component. The authors found that parkin and synphilin-1 coimmunoprecipitate from cell culture extracts and from rat brain homogenates. The interaction was localized to the second ring finger domain of parkin (R2) and the ankyrin domain of synphilin. Mutations in the R2 domain, which are associated with familial forms of PD, were found not only to increase the strength of the interaction, but also to inhibit or even abolish ubiquitination of synphilin. In addition, coexpression of all three proteins resulted in the formation of ubiquitinated inclusion bodies in vitro, yet when mutated forms of parkin were substituted for wild type the number of ubiquitinated inclusions dropped nearly 20-fold.

"This is a wonderful piece of work that closes the loop between parkin and α-synuclein," said Michael Schlossmacher, a neurologist at Brigham and Women's Hospital in Boston. "Perhaps more importantly, the authors have generated inclusion bodies in vitro that are morphologically very similar to Lewy bodies. These may serve as useful models for further study."-Tom Fagan.



Reference:Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J, Ross CA, Dawson VL, Dawson TM. Parkin ubiquitinates the a-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med. 2001 Oct;7(10):1144-50. Abstract

 
Comments on News and Primary Papers
  Comment by:  Matthew Held
Submitted 7 December 2006  |  Permalink Posted 8 December 2006
  I recommend the Primary Papers

The data in this paper provide an impetus for further investigation into synphilin-1 (Sph-1), especially with regards to post-translational modifications. As it has previously been shown that specific phosphorylation events in Sph-1 are necessary for protein aggregation in a cellular setting, experiments to elucidate modifications to this Sph-1A isoform are at an advantageous juncture. One should certainly strive to answer the questions: Which modifications are similar between Sph-1 and Sph-1A and which alterations recapitulate Lewy Body-like formation in neuronal settings? Are these modifications regulated by kinases such as Gsk3b or CKII? What E3 ligases (parkin, Siah, etc) are responsible, if any, for degradation of these modified versions? I would also have to agree with E. Junn and M. Mouradian that it is not clear as to whether or not Sph-1A creates aggregates moreso than its full-length form because of insolubility in Triton-X 100. As the protein was a fusion contruct with the viral protein hemagluttinin (HA), skepticism of their claim becomes paramount since HA has...  Read more
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad